ArticleCureus2022

First-line Rucaparib Plus Bevacizumab Maintenance Completed One-Year in Germline BRCA1-Mutated Advanced Ovarian Cancer.

Somnath Roy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.